Oncternal Therapeutics (FRA:GTU) Total Stockholders Equity : €21.09 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Total Stockholders Equity?

Oncternal Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €21.09 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Oncternal Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €7.13. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Oncternal Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.01.

Oncternal Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Oncternal Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Total Stockholders Equity Chart

Oncternal Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

12.88

92.85

77.99

57.56

27.56

Oncternal Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															49.02	41.71	34.67	27.56	21.09

Oncternal Therapeutics (FRA:GTU) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Oncternal Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(21.092	-	0)	/	2.95964
	=	7.13

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Oncternal Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.165	+	0.091)	/	21.092
	=	0.01

Oncternal Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (FRA:GTU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ONCT:USA

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines